Singapore-based biotech company Enleofen Bio is selling the worldwide exclusive rights of its biotech platform, Eneleofen’s preclinical interleukin-11 (IL-11), to global pharma major Boehringer Ingelheim, according to a press statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
